Good spot sleepingwolf, however as the pancreas produces most of the digestive juices it deteriorates immediately after death meaning that the number of patients that can be treated from human donation is minimal. Also the article does not mention that the patients need to be on toxic immunosurpressants to keep their implants intact. LCT's offering is a commercial one where the cells can be manufactured and harvested for application to a large number of patients. Once the JDRF realise that they can help a great number of kids by supporting LCT the share price should see significant movement.
LCT Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
